Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Semin Fetal Neonatal Med. 2022 Jun 3;27(4):101367. doi: 10.1016/j.siny.2022.101367

Fig. 1.

Fig. 1.

Pulmonary Hypertension Drug Therapies Target Endothelial Cell Derived Pulmonary Vasodilator Pathways. Nitric oxide (NO) and prostacyclin (PGI2) signaling pathways regulate pulmonary vascular tone in the developing lung. ATP, Adenosine triphosphate; cAMP, cyclic AMP; cGMP, cyclic GMP; COX-1, cyclooxygenase 1; GTP, guanosine triphosphate; NOS, nitric oxide synthase; PDE3, phosphodiesterase 3; PDE5, phosphodiesterase 5; PBF, pulmonary blood flow; PGIS, prostacyclin synthase. (Created with BioRender.com)